The VOWST Voyage™ program is here to support your patients

Financial assistance may be available for eligible patients

To get your patient started in the VOWST Voyage Patient Support program, you will need to complete and submit the VOWST® enrollment form and prescription either through the VOWST Voyage Prescriber Portal or print and fax.

How to enroll your patients:

Access the VOWST Voyage Presciber Portal OR Download the Enrollment Form

Patients are not required to enroll in VOWST Voyage to access VOWST.

Case managers

Once enrolled, a case manager will get in touch with the patient to discuss program details.

Coverage and benefits investigation

We can help your patients:

Navigate insurance coverage and benefits
Investigate other options for coverage, including financial assistance programs that may help cover some of the out-of-pocket costs of VOWST for eligible patients

CO-PAY ASSISTANCE

Eligible commercially insured patients may pay as little as $0 for VOWST, with a maximum benefit of $9,100 per calendar year.*

^*Offer not valid for patients whose prescriptions are reimbursed by Medicare, Medicaid, or other state or federal healthcare program, or where prohibited by law. To learn the full Terms, Conditions, and Eligibility requirements, visit VOWSTcopay.com.

VOWST PATIENT ASSISTANCE PROGRAM (PAP)

Uninsured or underinsured patients may be eligible to receive VOWST at no cost if they meet financial and other eligibility requirements.

Welcome kit

Patients enrolled in VOWST Voyage may be eligible to receive a complementary welcome kit, which includes a laxative (magnesium citrate).

Over 92% of commercial and Medicare insured patients have access to VOWST with no step therapy requirements,^† and over 90% of all first recurrent patients have been approved by payors nationally^‡

^†As of March 2024 and of published policies. Individual benefits may vary.

^‡Data on file based on Specialty Pharmacy dispensing data from May 10, 2023 to May 22, 2024.¹

ACCESS AND
REIMBURSEMENT RESOURCES

Explore available financial and educational materials

SEE RESOURCES

REQUEST A REP

Contact a VOWST representative to receive updates

CONTACT A VOWST REP

ABX, antibiotics.

REFERENCE: 1. Data on File. Nestlé Health Science.

ECOSPOR III
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff ^1-3
Primary Endpoint Recurrence at 8 weeks* Secondary Endpoints Adverse events within 24 weeks Recurrence at 4, 12, 24 weeks*
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)

ECOSPOR IV
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff ⁵
Primary Endpoint Adverse events within 24 weeks Secondary Endpoints Recurrence at 4, 8, 12, 24 weeks
Recurrence confirmed with C. diff toxin test or PCR and ≥3 unformed bowel movements per day over 2 days^*
10–42 days of vancomycin or 10–25 days of fidaxomicin